RSV vaccine response after stem cell or car-t therapy
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This trial studies how well the RSV vaccine works in people who have had a stem cell transplant or CAR-T therapy for a blood cancer. It aims to see if the vaccine can protect you from RSV, a common respiratory virus that can be serious for people with weakened immune systems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a blood cancer (such as leukemia, lymphoma, or myeloma).
- You have had a stem cell or bone marrow transplant, or CAR-T cell therapy.
- You are willing to give blood samples before and after the RSV vaccine (at 4 weeks and 6 months).
- Your insurance covers the cost of the RSV vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.
This trial tests two RSV vaccine schedules in people who have had a lung transplant or a stem cell transplant. It looks at whether the vaccines are safe and how well they boost the immune system against RSV, a common respiratory virus.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
This trial tests if remdesivir can safely treat RSV (a respiratory virus) in people with weakened immune systems, such as those who have had a stem cell or bone marrow transplant, CAR T-cell therapy, or are being treated for blood cancer. If you have a confirmed RSV infection in your nose or throat and are at moderate or high risk for complications, you may be able to join.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
Hear when a new CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.